Page 108 - 《中国药房》2024年21期

vs. low-dose mycophenolate mofetil in recurrence of 136（1）：e132-e139.
steroid-dependent nephrotic syndrome in children and [24] KAMEI K，OKADA M，SATO M，et al. Rituximab treat‐
young adults：a randomized clinical trial[J]. JAMA Pediatr， ment combined with methylprednisolone pulse therapy
2021，175（6）：631-632. and immunosuppressants for childhood steroid-resistant
[14] NAKAGAWA T，SHIRATORI A，KAWABA Y，et al. Effi‐ nephrotic syndrome[J]. Pediatr Nephrol，2014，29（7）：
cacy of rituximab therapy against intractable steroid- 1181-1187.
resistant nephrotic syndrome[J]. Pediatr Int，2016，58 [25] 白玲，陆晨. 利妥昔单抗治疗儿童特发性膜性肾病的疗
（10）：1003-1008. 效分析[J].世界最新医学信息文摘，2020，20（91）：1-2，5.
[15] SUN L，XU H，SHEN Q，et al. Efficacy of rituximab BAI L，LU C.Efficacy analysis of rituximab in the treat‐
therapy in children with refractory nephrotic syndrome：a ment of idiopathic membranous nephropathy in children
prospective observational study in Shanghai[J]. World J [J]. World Lat Med Informat，2020，20 （91）：1-2，5.
Pediatr，2014，10（1）：59-63. [26] 王美秋，王忍，夏正坤，等. 利妥昔单抗治疗难治性激素
[16] ZACHWIEJA J，SILSKA-DITTMAR M，ŻUROWSKA 耐药型肾病综合征的疗效和安全性[J]. 中华实用儿科临
A，et al. Multicenter analysis of the efficacy and safety of 床杂志，2021，36（5）：355-358.
a non-standard immunosuppressive therapy with rituxi- WANG M Q，WANG R，XIA Z K，et al. Efficacy and
mab in children with steroid-resistant nephrotic syndrome safety of rituximab in the treatment of refractory steroid-
[J]. Clin Exp Pharmacol Physiol，2019，46（4）：313-321. resistant nephrotic syndrome[J]. Chin J Appl Clin Pediatr，
[17] MAGNASCO A，RAVANI P，EDEFONTI A，et al. Rituxi- 2021，36（5）：355-358.
mab in children with resistant idiopathic nephrotic syn‐ [27] AL SALLOUM A A，AL HERBISH A J，AL HISSI M A，
drome[J]. J Am Soc Nephrol，2012，23（6）：1117-1124. et al. The outcome of rituximab in treating steroid depen‐
[18] 张喻，曲艺，董丽，等. 真实世界证据与随机对照试验证 dent nephrotic syndrome.：histopathology and immunosup‐
据比较研究[J]. 中国新药杂志，2021，30（11）：971-975. pressive drugs as predicting factors[J]. Saudi Med J，2022，
ZHANG Y，QU Y，DONG L，et al. A comparative study 43（7）：760-764.
of real-world evidence and randomized controlled trial evi‐ [28] SELLIER-LECLERC A L，BAUDOUIN V，KWON T，
dence[J]. Chin J N Drugs，2021，30（11）：971-975. et al. Rituximab in steroid-dependent idiopathic nephrotic
[19] 中华医学会儿科学分会肾脏学组. 儿童激素敏感、复发/ syndrome in childhood：follow-up after CD19 recovery[J].
依赖肾病综合征诊治循证指南：2016[J]. 中华儿科杂志， Nephrol Dial Transplant，2012，27（3）：1083-1089.
2017，55（10）：729-734. [29] CHAN E Y，WEBB H，YU E，et al. Both the rituximab
Nephrology Group，Pediatric Credits of the Chinese Medi‐ dose and maintenance immunosuppression in steroid-
cal Association. Evidence-based guidelines for diagnosis dependent/frequently-relapsing nephrotic syndrome have
and treatment of hormone sensitive，recurrent/dependent important effects on outcomes[J]. Kidney Int，2020，97
nephrotic syndrome in children：2016[J]. Chin J Pediatr， （2）：393-401.
2017，55（10）：729-734. [30] CHAN C Y，TEO S，LU L J，et al. Low regulatory T-cells：
[20] MUNN Z，BARKER T H，MOOLA S，et al. Methodologi‐ a distinct immunological subgroup in minimal change ne‐
cal quality of case series studies：an introduction to the phrotic syndrome with early relapse following rituximab
JBI critical appraisal tool[J]. JBI Evid Synth，2020，18 therapy[J]. Transl Res，2021，235：48-61.
（10）：2127-2133. [31] FUJINAGA S，HIRANO D，NISHIZAKI N，et al. Single
[21] 顾莺，张慧文，周英凤，等. JBI循证卫生保健中心关于不 infusion of rituximab for persistent steroid-dependent
同类型研究的质量评价工具：分析性研究的质量评价 minimal-change nephrotic syndrome after long-term cy‐
[J]. 护士进修杂志，2018，33（5）：400-403. closporine[J]. Pediatr Nephrol，2010，25（3）：539-544.
GU Y，ZHANG H W，ZHOU Y F，et al. The Joanna [32] KIM J H，PARK E，HYUN H S，et al. Long-term repeated
Briggs Institute critical appraisal tools used in systematic rituximab treatment for childhood steroid-dependent ne‐
reviews：analytic study[J]. J Nurses Train，2018，33（5）： phrotic syndrome[J]. Kidney Res Clin Pract，2017，36（3）：
400-403. 257-263.
[22] SINHA R，BANERJEE S，MUKHERJEE A，et al. Early [33] RAVANI P，PONTICELLI A，SICILIANO C，et al. Ritu-
use of rituximab in calcineurin inhibitor-refractory and ximab is a safe and effective long-term treatment for chil‐
steroid-resistant nephrotic syndrome[J]. Kidney Int Rep， dren with steroid and calcineurin inhibitor-dependent idio‐
2020，5（12）：2354-2357. pathic nephrotic syndrome[J]. Kidney Int，2013，84（5）：
[23] BASU B，MAHAPATRA T K S，MONDAL N. Mycophe‐ 1025-1033.
nolate mofetil following rituximab in children with [34] GOMES R，MOSCA S，BASTOS-GOMES M，et al.
steroid-resistant nephrotic syndrome[J]. Pediatrics，2015， Rituximab therapy for childhood onset idiopathic ne‐

· 2674 · China Pharmacy 2024 Vol. 35 No. 21 中国药房 2024年第35卷第21期